ExpreS2ion Biotech
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar! Pareto Securities publishes research report
This comprehensive report analyses recent updates to the company's platform technology and key assets, with a deep dive into the HER2+ breast cancer vaccine candidate ES2B-C001. It provides an assessment of the company's cash position and an updated sum-of-the-parts valuation. Pareto revised its price target to SEK 9.00 per share, with a “Buy” rating. The research report is available on the Analyst Reports page of ExpreS2ion’s investor website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
| Datum | 2023-12-04, kl 09:01 |
| Källa | Cision |